Steimer W - Search Results

1

MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?

Czerwensky F, Leucht S, Steimer W. Czerwensky F, et al. Among authors: steimer w. Int J Neuropsychopharmacol. 2013 Oct;16(9):2103-9. doi: 10.1017/S1461145713000849. Epub 2013 Aug 7. Int J Neuropsychopharmacol. 2013. PMID: 23920449 Free article.

2

Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients.

Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R. Leucht S, et al. Among authors: steimer w. Psychopharmacology (Berl). 2000 Jan;147(4):378-83. doi: 10.1007/s002130050006. Psychopharmacology (Berl). 2000. PMID: 10672631 Clinical Trial.

3

Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy.

Steimer W, Müller B, Leucht S, Kissling W. Steimer W, et al. Clin Chim Acta. 2001 Jun;308(1-2):33-41. doi: 10.1016/s0009-8981(01)00423-5. Clin Chim Acta. 2001. PMID: 11412815 Review.

4

Doxepin plasma concentrations: is there really a therapeutic range?

Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Leucht S, et al. Among authors: steimer w. J Clin Psychopharmacol. 2001 Aug;21(4):432-9. doi: 10.1097/00004714-200108000-00011. J Clin Psychopharmacol. 2001. PMID: 11476128

5

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.

Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Steimer W, et al. Clin Chem. 2004 Sep;50(9):1623-33. doi: 10.1373/clinchem.2003.030825. Epub 2004 Jun 17. Clin Chem. 2004. PMID: 15205367

6

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Steimer W, et al. Clin Chem. 2005 Feb;51(2):376-85. doi: 10.1373/clinchem.2004.041327. Epub 2004 Dec 8. Clin Chem. 2005. PMID: 15590749 Clinical Trial.

7

Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study.

Popp J, Leucht S, Heres S, Steimer W. Popp J, et al. Among authors: steimer w. Pharmacogenomics. 2006 Mar;7(2):159-66. doi: 10.2217/14622416.7.2.159. Pharmacogenomics. 2006. PMID: 16515395 Clinical Trial.

8

ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline.

Laika B, Leucht S, Steimer W. Laika B, et al. Among authors: steimer w. Clin Chem. 2006 May;52(5):893-5. doi: 10.1373/clinchem.2006.066605. Clin Chem. 2006. PMID: 16638956 No abstract available.

9

DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.

Popp J, Leucht S, Heres S, Steimer W. Popp J, et al. Among authors: steimer w. Pharmacogenomics J. 2009 Feb;9(1):71-7. doi: 10.1038/tpj.2008.5. Epub 2008 Mar 11. Pharmacogenomics J. 2009. PMID: 18332898 Clinical Trial.

10

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

Laika B, Leucht S, Heres S, Steimer W. Laika B, et al. Among authors: steimer w. Pharmacogenomics J. 2009 Dec;9(6):395-403. doi: 10.1038/tpj.2009.23. Epub 2009 May 19. Pharmacogenomics J. 2009. PMID: 19451914

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page